- Home
- KMDA vs ATYR Comparison
KMDA vs ATYR Comparison
Compare KMDA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- ATYR
- Stock Information
- Founded
- KMDA 1990
- ATYR 2005
- Country
- KMDA Israel
- ATYR United States
- Employees
- KMDA N/A
- ATYR N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KMDA Health Care
- ATYR Health Care
- Exchange
- KMDA Nasdaq
- ATYR Nasdaq
- Market Cap
- KMDA 443.4M
- ATYR 451.3M
- IPO Year
- KMDA N/A
- ATYR 2015
- Fundamental
- Price
- KMDA $7.72
- ATYR $5.83
- Analyst Decision
- KMDA Strong Buy
- ATYR Strong Buy
- Analyst Count
- KMDA 2
- ATYR 6
- Target Price
- KMDA $13.00
- ATYR $20.20
- AVG Volume (30 Days)
- KMDA 55.4K
- ATYR 5.4M
- Earning Date
- KMDA 08-13-2025
- ATYR 08-12-2025
- Dividend Yield
- KMDA 2.59%
- ATYR N/A
- EPS Growth
- KMDA 31.21
- ATYR N/A
- EPS
- KMDA 0.28
- ATYR N/A
- Revenue
- KMDA $167,235,000.00
- ATYR N/A
- Revenue This Year
- KMDA $14.51
- ATYR $551.06
- Revenue Next Year
- KMDA $9.31
- ATYR $1,874.58
- P/E Ratio
- KMDA $28.31
- ATYR N/A
- Revenue Growth
- KMDA 11.83
- ATYR N/A
- 52 Week Low
- KMDA $5.08
- ATYR $1.67
- 52 Week High
- KMDA $9.16
- ATYR $7.10
- Technical
- Relative Strength Index (RSI)
- KMDA 53.97
- ATYR 54.71
- Support Level
- KMDA $7.64
- ATYR $5.15
- Resistance Level
- KMDA $7.91
- ATYR $7.10
- Average True Range (ATR)
- KMDA 0.18
- ATYR 0.55
- MACD
- KMDA -0.02
- ATYR -0.00
- Stochastic Oscillator
- KMDA 50.00
- ATYR 37.44
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.